S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Applied Optoelectronics earnings dumper, pain now for gain later?
Are NFTs Back? Why NFTs Will Make a Comeback in 2024

Atrion (ATRI) Competitors

$362.99
+11.69 (+3.33%)
(As of 02/28/2024 ET)

ATRI vs. KIDS, OSUR, CERS, ANIK, UTMD, NVRO, SILK, IRMD, LUNG, and OFIX

Should you be buying Atrion stock or one of its competitors? The main competitors of Atrion include OrthoPediatrics (KIDS), OraSure Technologies (OSUR), Cerus (CERS), Anika Therapeutics (ANIK), Utah Medical Products (UTMD), Nevro (NVRO), Silk Road Medical (SILK), IRadimed (IRMD), Pulmonx (LUNG), and Orthofix Medical (OFIX). These companies are all part of the "medical" sector.

Atrion vs.

Atrion (NASDAQ:ATRI) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

OrthoPediatrics has a consensus price target of $42.50, indicating a potential upside of 54.88%. Given OrthoPediatrics' higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Atrion.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OrthoPediatrics
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Atrion has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Atrion has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Atrion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$183.51M3.48$35.01M$12.0830.05
OrthoPediatrics$122.29M5.24$1.26M-$0.98-28.00

OrthoPediatrics received 173 more outperform votes than Atrion when rated by MarketBeat users. Likewise, 64.39% of users gave OrthoPediatrics an outperform vote while only 56.33% of users gave Atrion an outperform vote.

CompanyUnderperformOutperform
AtrionOutperform Votes
129
56.33%
Underperform Votes
100
43.67%
OrthoPediatricsOutperform Votes
302
64.39%
Underperform Votes
167
35.61%

Atrion has a net margin of 12.64% compared to OrthoPediatrics' net margin of -15.57%. Atrion's return on equity of 8.89% beat OrthoPediatrics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atrion12.64% 8.89% 8.06%
OrthoPediatrics -15.57%-5.58%-4.88%

In the previous week, OrthoPediatrics had 4 more articles in the media than Atrion. MarketBeat recorded 7 mentions for OrthoPediatrics and 3 mentions for Atrion. Atrion's average media sentiment score of 0.36 beat OrthoPediatrics' score of 0.25 indicating that Atrion is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atrion
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
OrthoPediatrics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

65.7% of Atrion shares are owned by institutional investors. Comparatively, 68.4% of OrthoPediatrics shares are owned by institutional investors. 22.7% of Atrion shares are owned by company insiders. Comparatively, 32.6% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

OrthoPediatrics beats Atrion on 9 of the 17 factors compared between the two stocks.


Get Atrion News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATRI vs. The Competition

MetricAtrionSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$638.86M$3.67B$4.96B$7.45B
Dividend Yield2.49%2.16%2.90%3.88%
P/E Ratio30.0515.99225.8416.90
Price / Sales3.4827.553,032.6664.65
Price / Cash12.8525.6094.9854.63
Price / Book2.694.004.474.66
Net Income$35.01M$7.89M$112.56M$210.60M
7 Day Performance0.03%1.75%5.15%2.49%
1 Month Performance13.44%49.00%13.01%4.77%
1 Year Performance-36.09%1.49%11.94%7.50%

Atrion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KIDS
OrthoPediatrics
3.8995 of 5 stars
$28.79
-2.3%
$42.50
+47.6%
-37.7%$672.25M$122.29M-29.38203Upcoming Earnings
News Coverage
OSUR
OraSure Technologies
3.2891 of 5 stars
$6.82
+1.0%
$6.33
-7.1%
+25.1%$501.13M$387.48M10.33840Earnings Report
News Coverage
Gap Up
CERS
Cerus
3.4894 of 5 stars
$2.31
-2.1%
$3.00
+29.9%
-22.8%$418.57M$162.05M-8.25665Upcoming Earnings
ANIK
Anika Therapeutics
2.5575 of 5 stars
$24.25
+0.2%
$26.00
+7.2%
-21.0%$355.04M$163.31M-14.35345Short Interest ↑
UTMD
Utah Medical Products
2.8985 of 5 stars
$72.76
+0.5%
N/A-23.5%$264.12M$50.22M15.92186Analyst Upgrade
NVRO
Nevro
2.1744 of 5 stars
$17.19
-0.8%
$24.00
+39.6%
-53.7%$622.45M$406.36M-6.011,087Analyst Revision
SILK
Silk Road Medical
3.1394 of 5 stars
$17.15
-6.0%
$24.91
+45.2%
-66.9%$667.82M$138.64M-11.83414News Coverage
IRMD
IRadimed
4.8912 of 5 stars
$44.90
-1.3%
$60.00
+33.6%
+9.9%$566.19M$65.56M33.01123Short Interest ↑
LUNG
Pulmonx
3.0983 of 5 stars
$14.41
+0.6%
$14.17
-1.7%
-14.8%$552.05M$53.66M-8.90269Short Interest ↓
High Trading Volume
OFIX
Orthofix Medical
0.2354 of 5 stars
$13.76
-0.2%
$14.00
+1.7%
-36.1%$505.82M$460.71M-3.531,092Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:ATRI) was last updated on 2/29/2024 by MarketBeat.com Staff